🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Germany
Clinical trial register · European Union · CTIS

Clinical Trials in Germany

The most recently authorised trials on the EU Clinical Trials Information System (CTIS), the single register for every trial run under the EU Clinical Trials Regulation (536/2014). CTIS holds a far larger historical archive than any one list can usefully show — this register states both numbers rather than picking one.

Download CSV
Source: EMA Clinical Trials Information System (CTIS). Showing the 2500 most recently authorised of 12445 total CTIS records — a stated recency window, not the full historical archive. Synced 21 Sep 2026, 03:16 UTC
2500
Shown in this register
most recently authorised
12,445
Total on CTIS
full historical archive
745
Phase III
within the shown window
Top member states
Spain 1023 France 890 Germany 861 Italy 742 Poland 587 Netherlands 524
Narrow the registerReset
Phase
Phase I 558 Phase I/II 214 Phase II 726 Phase III 745 Phase IV 257
Lead sponsor
AstraZeneca AB 60 Assistance Publique Hopitaux De Paris 49 Merck Sharp & Dohme LLC 48 Pfizer Inc. 45 Novo Nordisk A/S 42
Member state
Spain 1023 France 890 Germany 861 Italy 742 Poland 587 Netherlands 524 Belgium 426 Czechia 327
All 28 states
142 of 2500 shown studies
Download
Phase
Study
Lead sponsor
Area
Member states
Decision
Phase I
An Early-Stage Study in Multiple Clinics of how Afimkibart May Affect the Body’s Processing of Medicines that Rely on Cytochrome P450 Enzymes in Patients with Ulcerative Colitis
2025-524060-38-00Active Ulcerative Colitis (UC)
F. Hoffmann-La Roche AG
Digestive System Diseases
Germany, Poland, Belgium
19/05/2026
Phase I
A multi-part study to investigate MTX325 in healthy volunteers and patients with Parkinson's Disease
2024-517310-15-00Parkinson's Disease
Mission Therapeutics Limited
Nervous System Diseases
Germany, Netherlands, France
18/05/2026
Phase I
A three-part first-in-human trial to assess safety, tolerability, pharmacokinetics and pharmacodynamics of GUB-UCN2 in healthy lean and obese participants and participants with T2D
2025-524921-42-00Type 2 Diabetes, Obesity
Gubra A/S
Nutritional and Metabolic Diseases
Germany
11/05/2026
Phase I
A Study to Assess the Safety of RG6496 in Huntington’s Disease Gene Expansion Carriers with the Selected Genetic Variant (POINT-HD)
2025-520631-17-00Huntington’s Disease Gene Expansion Carriers
F. Hoffmann-La Roche AG
Nervous System Diseases
Italy, Poland, Denmark, Germany, Portugal, Spain
11/05/2026
Phase I
A study to investigate a potential effect of rilzabrutinib (SAR444671) on ethinylestradiol and levonorgestrel from combined oral contraceptives in healthy female participants
2026-525350-11-00Immune Thrombocytopenia Purpura
Sanofi-Aventis Recherche & Developpement
Immune System Diseases
Germany
11/05/2026
Phase I
Phase 1b Study of Tarlatamab + ZL-1310 +/- Anti-PD-L1 in Small Cell Lung Cancer
2025-522888-15-00Small Cell Lung Cancer
Amgen Inc.
Neoplasms
Spain, Germany, Poland, Belgium, France
05/05/2026
Phase I
A Phase I, open-label study in healthy adults comparing the availability in the body of the active substance lidocaine following administration of 2% and 4% lidocaine gel into the urethra
2026-525752-29-00bioavailability trial with healthy participants, therapeuti…
Farco-Pharma GmbH
Anesthesia and Analgesia
Germany
05/05/2026
Phase I
An open-label, single-center study to evaluate the safety and test-retest characteristics of [11C]MODAG-005 as PET radioligand for imaging pathological alpha-synuclein deposition in the brains of patients with Parkinson’s disease (PD) or Multiple System Atrophy (MSA) compared to age-matched healthy controls (AMHC)
2023-506965-72-00Parkinson Disease, Multiple System Atrophy, Healthy Volunte…
Modag GmbH
Not possible to specify
Germany
04/05/2026
Phase I
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants with Atopic Dermatitis
2025-524205-32-00Atopic Dermatits
Regeneron Pharmaceuticals Inc.
Skin and Connective Tissue Diseases
Belgium, Czechia, Germany, Poland
30/04/2026
Phase I
A study in healthy people or otherwise healthy but overweight or obese to compare 2 formulations of survodutide given in different ways, either as a pre-filled syringe or a pen-like injector
2025-524135-39-00Healthy volunteer trial
Boehringer Ingelheim International GmbH
Not possible to specify
Germany
28/04/2026
Phase I
A research study investigating the effect of NNC0497-0040 in healthy participants, participants with overweight or obesity, and participants with type 1 diabetes with overweight or obesity.
2025-523978-16-00Type I diabetes
Novo Nordisk A/S
Nutritional and Metabolic Diseases
Germany
23/04/2026
Phase I
Clinical Study to Evaluate the Effects of Cevostamab in Patients with Lupus with or without Active Lupus Nephritis
2025-522904-26-00Systemic Lupus Erythematosus (SLE) With or Without Active L…
Genentech Inc.
Immune System Diseases
Italy, Spain, France, Germany
22/04/2026
Phase I
A research study to compare blood levels of cagrilintide after multiple doses of different versions of cagrilintide in adults with overweight or obesity
2025-521384-12-00obesity
Novo Nordisk A/S
Nutritional and Metabolic Diseases
Germany
21/04/2026
Phase I
A study to test how well different doses of BI 3820768 are tolerated by people with advanced cancer (solid tumours)
2025-522913-45-00Advanced relapsed or refractory ovarian cancer, Advanced re…
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.
Neoplasms
Spain, France, Belgium, Germany
20/04/2026
Phase I
A Phase 1 Study of AIR-001 in Adults with AATD.
2025-523558-14-00Alpha-1 Antitrypsin Deficiency
Airna Corp.
Respiratory Tract Diseases
Sweden, Ireland, Spain, Netherlands, Portugal, Germany
17/04/2026
Phase I
A Phase 1b, Double-Blind Study to Investigate Safety, Tolerability, Pharmacokinetics, Efficacy, and Pharmacodynamics of Single Dose of ATI-052 in Participants with Mild to Moderate Asthma
2025-524987-39-00Mild to Moderate Asthma
Aclaris Therapeutics Inc.
Respiratory Tract Diseases
Germany
16/04/2026
Phase I
GRT-1C102: A randomized, double-blind, placebo-controlled dose escalation study to evaluate the safety, tolerability, and pharmacokinetics/pharmacodynamics of GRT-001 after subcutaneous administrations to healthy subjects (MONOSqut trial).
2025-524328-24-00Ulcerative colitis
Granite Bio AG
Digestive System Diseases
Germany
15/04/2026
Phase I
A study in healthy men to test how bosentan influences the amount of zongertinib in the blood
2025-523193-16-00Healthy volunteer trial
Boehringer Ingelheim International GmbH
Not possible to specify
Germany
15/04/2026
Phase I
A study to learn more about the safety and effects of a new blood-thinning medicine, given alone and together with another blood-thinner, in healthy adults
2025-524043-12-00atrial fibrillation, transient ischemic attack (TIA), ische…
Bayer AG
Cardiovascular Diseases
Germany
15/04/2026
Phase I
Study of diclofenac skin reservoir formation and emptying after Voltaren Emulgel 2.32% application in healthy participants
2025-524764-38-00For the local, symptomatic treatment of pain in acute bruis…
Haleon CH SARL
Therapeutics
Germany
09/04/2026
Phase I
A research study looking into how cagrilintide influences food intake and appetite in people with overweight or obesity
2025-524206-15-00Obesity
Novo Nordisk A/S
Nutritional and Metabolic Diseases
Germany
02/04/2026
Phase I
Study in healthy male participants to compare the blood levels after epoetin alfa (Blau EPO) and Erypo, administered as multiple intravenous injections as well as safety, tolerability and the effects on certain blood values.
2025-522246-43-00Treatment of symptomatic anemia associated with chronic ren…
Blau Farmaceutica S.A.
Hemic and Lymphatic Diseases
Germany
02/04/2026
Phase I
A multiCenter phase I study of aUtologous CD19 CAR T cElls for therapy refractory chronic GvHD (CURE-cGvHD)
2025-524468-40-00chronic Graft-versus-Host-Disease (cGvHD)
Universitaetsklinikum Erlangen AöR
Immune System Diseases
Germany
27/03/2026
Phase I
A study to learn about how a new nurandociguat tablet is absorbed and processed in the body compared to an old tablet and how food affects the way the new tablet is absorbed and processed in the body
2025-524176-36-00Chronic Kidney Disease
Bayer AG
Cardiovascular Diseases
Germany
25/03/2026
Phase I
A study to investigate the safety, pharmacokinetics, pharmacodynamics, and immunogenicity of a CD19/CD20 T-cell engager in participants with B-cell driven ARD.
2025-522932-15-00Systemic Lupus Erythematosus
Glaxosmithkline Research & Development Limited
Immune System Diseases
Germany, France, Italy, Spain, Poland
23/03/2026
Rows per page Showing 51–75 of 142
Previous 1 2 3 4 5 Next
Cite this view

Priya Life Science (2026). EU Clinical Trials Register (CTIS), filtered. Derived from the EMA Clinical Trials Information System. Retrieved 21 September 2026. https://priyalifescience.com/clinical-trials-europe/country/germany

Query this register directly
GET /api/export.php?register=trials-eu&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Looking for Irish sites? See the Ireland, UK or USA registers. For approved medicines, see the EMA Approvals Tracker.